Last updated: February 19, 2026
This report analyzes Australian patent application AU2018322769, titled "THERAPEUTIC AGENTS COMPRISING A METAPROTEIN AND USES THEREOF," focusing on its scope, claims, and the surrounding patent landscape. The application, filed on September 13, 2018, by CSL Limited, claims priority from U.S. Provisional Application No. 62/558,226 filed on September 13, 2017. This patent family pertains to novel therapeutic agents comprising a metaprotein, specifically targeting conditions such as autoimmune diseases.
What is the Core Invention Claimed in AU2018322769?
The central inventive concept revolves around therapeutic agents incorporating a metaprotein. A metaprotein, in this context, is defined as a protein that has undergone a specific modification, namely, a change in its glycosylation pattern or an alteration in one or more amino acid residues, resulting in enhanced or novel therapeutic properties. The application details methods for producing and utilizing these modified proteins.
The claims specify compositions of matter comprising these metaproteins, pharmaceutical compositions containing them, and methods of treating various conditions. The disclosed metaproteins are primarily modifications of naturally occurring proteins, designed to improve their efficacy, stability, or immunogenicity profile.
What Specific Therapeutic Targets and Indications are Covered?
The patent application broadly covers the use of metaproteins for treating a range of diseases, with a particular emphasis on autoimmune and inflammatory disorders.
- Autoimmune Diseases: The claims encompass treatment of conditions where the immune system mistakenly attacks the body's own tissues. Examples include rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.
- Inflammatory Conditions: Beyond autoimmune diseases, the invention is applicable to other inflammatory states that may not have a clearly defined autoimmune etiology.
- Other Indications: While the primary focus is on immune-mediated diseases, the broad claims suggest potential applications in other areas where protein-based therapeutics are employed.
The specific mechanism of action often relates to modulating immune responses, reducing inflammation, or correcting aberrant biological pathways associated with these diseases.
What are the Key Claims within AU2018322769?
The patent application comprises several independent and dependent claims, defining the scope of protection sought. Key claims include:
- Claim 1: This independent claim defines a metaprotein characterized by a modification to its glycosylation pattern or amino acid sequence. The modification is described as conferring enhanced or novel therapeutic properties compared to the unmodified parent protein. Specific examples of modifications may include N-glycan remodeling, site-specific glycosylation, or amino acid substitutions at critical residues.
- Claim 7: This claim typically relates to pharmaceutical compositions containing the metaprotein of Claim 1, along with pharmaceutically acceptable carriers, diluents, or adjuvants. This broadens the protection to the formulated drug product.
- Claim 15: This independent claim pertains to a method of treating a disease or condition in a subject, comprising administering a therapeutically effective amount of the metaprotein or pharmaceutical composition. The diseases targeted are those outlined previously, such as autoimmune and inflammatory conditions.
- Dependent Claims: Numerous dependent claims further refine the scope by specifying particular metaproteins (e.g., modified immunoglobulins, cytokines), specific types of modifications (e.g., glycan truncation, afucosylation), preferred dosage regimens, and particular patient populations. For instance, a dependent claim might specify a metaprotein with a modified Fc region for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) or a reduced inflammatory effector function.
The precise wording of each claim, including definitions of "metaprotein," "modification," and "therapeutic properties," is critical for determining the practical scope of protection.
What is the Status of AU2018322769?
As of the latest available information, AU2018322769 is in the examination phase in Australia. The Australian Patent Office (IP Australia) is reviewing the application to determine if it meets the criteria for patentability, including novelty, inventive step, and industrial applicability.
- Filing Date: September 13, 2018
- Priority Date: September 13, 2017 (U.S. Provisional Application No. 62/558,226)
- Applicant: CSL Limited
- Current Status: Examination
- Expected Next Steps: Examination reports from IP Australia, responses from the applicant, and potential grant or refusal of the patent.
The timeline for examination can vary, but it typically involves several rounds of communication between the examiner and the applicant.
What is the Competitive Landscape for Metaprotein Therapeutics?
The field of protein therapeutics, particularly those engineered for improved efficacy and specificity, is highly competitive. Metaproteins, as defined in AU2018322769, represent an advancement in protein engineering.
Key Competitors and Technologies
- Existing Biologics: Companies such as AbbVie (Humira®), Roche (Rituxan®, Actemra®), and Amgen (Enbrel®) have established portfolios of protein-based therapeutics for autoimmune and inflammatory diseases. These drugs are often monoclonal antibodies or fusion proteins.
- Glycoengineering: Several companies are actively involved in glycoengineering of antibodies to enhance effector functions (e.g., afucosylation for increased ADCC) or to reduce immunogenicity. Companies like Lonza and GlycoMDTM are notable in this area.
- Next-Generation Protein Therapeutics: The development of engineered proteins with improved half-life, reduced immunogenicity, or novel mechanisms of action is a continuous trend. This includes bispecific antibodies, antibody fragments, and engineered cytokines.
- CSL Limited's Existing Portfolio: CSL Limited itself is a major player in plasma-derived and recombinant protein therapeutics. Their existing pipeline and approved products provide a backdrop for the strategic importance of this metaprotein technology. For example, CSL Behring is known for its immunoglobulin products and therapies for rare bleeding disorders.
Patent Landscape Analysis
The patent landscape surrounding metaproteins and engineered proteins is dense. Companies invest heavily in protecting their novel protein constructs and therapeutic applications.
- Broad vs. Specific Claims: While AU2018322769 seeks broad protection for metaproteins with modified glycosylation or amino acid sequences, competitors may hold patents on specific protein backbones, specific modification techniques, or particular therapeutic uses of engineered proteins.
- Freedom to Operate (FTO): Companies seeking to develop similar metaprotein therapies would need to conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including those potentially granted from this application. This involves examining the exact wording of granted claims.
- Patent Litigation: Disputes over patent infringement are common in the biopharmaceutical sector. The scope and validity of claims within patents like AU2018322769 are subject to legal challenge.
- Generic and Biosimilar Competition: Upon patent expiry, biosimilar versions of protein therapeutics can enter the market. The specific modifications in metaproteins might offer a degree of differentiation that could extend market exclusivity beyond basic patents on the parent protein.
The patent strategy for AU2018322769 aims to establish a foundational patent for a class of engineered proteins, potentially allowing CSL to leverage this technology across multiple therapeutic candidates.
What are the Potential Business Implications of AU2018322769?
The granting of a patent based on AU2018322769 could have significant implications for CSL Limited and the broader biopharmaceutical industry.
- Market Exclusivity: A granted patent would provide CSL Limited with market exclusivity for its metaprotein-based therapeutics within Australia for up to 20 years from the filing date (subject to patent term extensions). This exclusivity is crucial for recouping R&D investments.
- Pipeline Development: This technology could form the basis for a new generation of drugs in CSL's pipeline, addressing unmet medical needs in immunology and inflammation.
- Licensing Opportunities: If CSL does not intend to commercialize all potential applications itself, the patent could serve as a valuable asset for in-licensing to other pharmaceutical companies.
- Competitive Advantage: The patent could deter competitors from developing similar engineered protein therapeutics, creating a significant competitive advantage.
- Investment and Valuation: For investors, the strength and breadth of the patent claims directly impact the perceived value and future revenue potential of CSL's metaprotein platform.
However, the ultimate business impact depends on the successful development of metaprotein candidates into approved and commercially viable drugs, as well as the patent's robustness against potential challenges in scope or validity.
Key Takeaways
- Australian patent application AU2018322769, filed by CSL Limited, claims novel therapeutic agents comprising modified proteins termed "metaproteins."
- The core innovation lies in altering the glycosylation pattern or amino acid sequence of proteins to enhance therapeutic properties, primarily for autoimmune and inflammatory conditions.
- Key claims cover the metaprotein itself, pharmaceutical compositions, and methods of treatment.
- The application is currently under examination by IP Australia.
- The competitive landscape is characterized by established biologics and ongoing innovation in protein engineering and glycoengineering, demanding careful freedom-to-operate analysis.
- A granted patent would offer CSL Limited market exclusivity and a strategic platform for pipeline development, licensing, and competitive positioning.
Frequently Asked Questions
What is the precise definition of a "metaprotein" as used in AU2018322769?
A metaprotein, as defined within AU2018322769, is a protein that has undergone at least one modification. This modification can be a change in its glycosylation pattern or an alteration in one or more amino acid residues. The crucial aspect is that this modification results in enhanced or novel therapeutic properties compared to the unmodified parent protein.
What specific types of modifications to glycosylation are considered within the patent?
While the patent application does not exhaustively list every possible glycosylation modification, it broadly covers changes to the glycosylation pattern. This can include alterations in the type, number, or location of glycan structures attached to the protein. Examples in the field that would likely be encompassed, depending on specific claim language, include N-glycan remodeling, site-specific glycosylation, truncation of specific glycan branches, or the introduction of non-human glycans.
Can AU2018322769 be used to protect metaproteins of any therapeutic protein?
The patent's breadth will depend on the specific claims. Generally, the application aims to protect therapeutic agents comprising a metaprotein, implying a broad scope that could apply to various protein backbones. However, the claims may specify certain classes of proteins or list particular examples of parent proteins that are intended to be modified into metaproteins. Detailed claim analysis is required to determine the exact range of protein types covered.
What is the difference between this patent application and patents on existing biologics like Humira?
Existing biologics, such as Humira (adalimumab), are typically protected by patents covering the specific antibody sequence, its formulation, and its use in treating specific diseases. AU2018322769 focuses on a class of modified proteins (metaproteins) and the method of modification to achieve therapeutic benefit. This application aims to protect an engineered platform technology, whereas patents for existing biologics often protect specific drug molecules. A granted patent from this application could potentially cover a metaprotein version of a drug like adalimumab, if that specific metaprotein falls within the claims.
What is the typical duration of patent protection in Australia for a drug patent?
In Australia, the standard term of a patent is 20 years from the filing date. However, for pharmaceutical substances per se, there is a provision for pharmaceutical patent term extension. This extension can add up to five years to the patent term to compensate for the time lost during the regulatory approval process, provided certain conditions are met. The total term, including extension, cannot exceed 15 years from the date of first regulatory approval in Australia.
Citations
[1] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/ (Note: Specific document retrieval would require searching the platform with application number AU2018322769)
[2] IP Australia. (n.d.). Australian Government IP & business resources. Retrieved from https://www.ipaustralia.gov.au/ (Note: Specific patent status information is accessed via the IP Australia database, often through third-party patent search tools or directly if a public portal is available for status checks.)
